Literature DB >> 10104285

Rheumatology referral patterns.

R S Hooker1, J B Brown.   

Abstract

The authors studied the characteristics of patients referred for rheumatology consultation in a group model HMO. Six hundred twelve patients were evaluated in 1986. The ages ranged from 3 to 85 years, with an average of 52 years. Female patients outnumbered male patients almost 3:1. Only 44% of referrals had a presumptive diagnosis and more than one half of these diagnoses were changed by the consulting rheumatology specialist, suggesting a high value added from the HMO rheumatologic consultation. Internists referred at a slightly higher rate than family practitioners, and pediatricians referred children at one tenth of the adult rate. Comparison with other published data on fee-for-service rheumatology practices indicates that in one group model HMO, which prohibits patient self-referral, rheumatologic specialists see a higher percentage of patients with vague or difficult-to-manage conditions such as the connective tissue diseases and fibromyalgia and a lower percentage of osteoarthritis and gout. This finding suggests that the structure and incentives of HMOs alter medical referral and practice patterns in significant ways.

Entities:  

Mesh:

Year:  1990        PMID: 10104285

Source DB:  PubMed          Journal:  HMO Pract        ISSN: 0891-6624


  3 in total

1.  Reasons for outpatient referrals from generalists to specialists.

Authors:  M T Donohoe; R L Kravitz; D B Wheeler; R Chandra; A Chen; N Humphries
Journal:  J Gen Intern Med       Date:  1999-05       Impact factor: 5.128

2.  Use of physician assistants in a managed health care system.

Authors:  R S Hooker; D K Freeborn
Journal:  Public Health Rep       Date:  1991 Jan-Feb       Impact factor: 2.792

3.  Lag time between onset of symptoms and diagnosis in Venezuelan patients with rheumatoid arthritis.

Authors:  Elaudi Rodríguez-Polanco; Soham Al Snih; Yong-Fang Kuo; Alberto Millán; Martín A Rodríguez
Journal:  Rheumatol Int       Date:  2010-01-12       Impact factor: 2.631

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.